Please login to the form below

Not currently logged in
Email:
Password:

Novartis warned on Exelon promotion for Alzheimerís disease

Novartis' promotion for mild-to-moderate Alzheimer's disease drug Exelon has made misleading claims about the medicine's effectiveness and risks, warns the FDA

Swiss-based pharmaceutical company Novartis' promotion for mild-to-moderate Alzheimer's drug Exelon (rivastigmine) has made misleading claims about the medicine's effectiveness and risks, according to FDA officials.

The FDA letter referred to a promotion for Exelon capsules and oral solution. Novartis also sells an Exelon patch.

The claims appeared on a file card written for health-care professionals about Exelon capsules and oral solution, according to the FDA. The agency asked Novartis to stop using the material and to circulate new information to correct misleading statements.

The FDA said the Novartis file card exaggerated Exelon's benefits and suggested its use with another Alzheimer's drug, Forest Laboratories' Namenda (memantine), a combination which is not approved by the agency.

The FDA added that various presentations of the drug's safety were misleading. One section titled "Safety Profile" failed to mention serious risks including gastrointestinal reactions. Global FY06 sales of Exelon were USD 525m.

The FDA letter can be found on the FDA website: http://www.fda.gov/cder/warn/2007/Exelon_wl.pdf

15th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...